Provided by Tiger Trade Technology Pte. Ltd.

Invesco Dorsey Wright Healthcare Momentum ETF

58.76
+1.392.43%
Post-market: 58.800.0430+0.07%19:30 EDT
Volume:17.38K
Turnover:1.02M
Market Cap:284.38M
PE:19.22
High:59.14
Open:57.66
Low:57.66
Close:57.37
52wk High:64.10
52wk Low:44.47
Shares:4.84M
Float Shares:4.84M
Volume Ratio:0.51
T/O Rate:0.36%
Dividend:1.53
Dividend Rate:2.60%
EPS(TTM):3.06
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Roivant Sciences Ltd - Study Also Met Its Secondary Endpoints at Week 16

THOMSON REUTERS
·
Sep 08

Guardant Health initiated with a Buy at Rothschild & Co Redburn

TIPRANKS
·
Sep 08

China Securities Reports Medical Device Sector Sustains Earnings Improvement While Medical Services Revenue Grows Steadily

Stock News
·
Sep 08

Medical Device Inspection Campaign Launched by Ningyang County Market Regulators

Deep News
·
Sep 07

MedTech Firm Joins Hong Kong Market: Evaluating MEDCAPTAIN's (02041) True Investment Potential

Stock News
·
Sep 07

Roivant to Present Phase 2 PHocus Mosliciguat Topline Data in PH-ILD at ERS Congress Sept. 8, 2026

Reuters
·
Sep 06

Brain-Computer Interface Startups Must Walk the Line Between Vast Potential and Near-Term Medical Reality, Says Formatia Founder

Deep News
·
Sep 05

Guardant announces FDA approval of Guardant360 CDx as companion diagnostic

TIPRANKS
·
Sep 05

Guardant Health Announces Landmark FDA Approval of Guardant360® Cdx as Companion Diagnostic for AstraZeneca’s Etcamah™ (Camizestrant) in Advanced Breast Cancer

THOMSON REUTERS
·
Sep 05

Axsome COO Mark Jacobson Sells 10,000 Shares for $2.09 Million

Reuters
·
Sep 04

Immunovant Holds Annual Stockholder Meeting with 96% Shares Represented

Reuters
·
Sep 04

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), Teva Pharmaceutical (TEVA)

TIPRANKS
·
Sep 03

Yinchuan Market Regulators Roll Out Comprehensive Measures to Implement Revised Medical Device Production Quality Standards

Deep News
·
Sep 03

Buy Rating Reiterated on Daraxonrasib Strength, RASolve 301 Upsizing, and Unchanged $315 Price Target

TIPRANKS
·
Sep 03

NEJM publishes Phase 1/2 clinical data on daraxonrasib

TIPRANKS
·
Sep 03

New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer

GlobeNewswire
·
Sep 03

Revolution Medicines Director Lorence H. Kim Disposes of Common Shares Worth $11.21 Million

Reuters
·
Sep 03

Shenzhen Regulator Launches 2026 Roadshow Selection for Key Medical Device Innovation Projects

Deep News
·
Sep 02

Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
Sep 02

Guardant Health Price Target Maintained with a $195.00/Share by BTIG

Dow Jones
·
Sep 02